Jiuzhou Pharmaceuticals: Subsidiary passes on-site inspection by the US FDA.

Jiuzhou Pharmaceutical announced that its subsidiary Ruibo Pharmaceutical Co., Ltd. underwent an on-site cGMP inspection by the US Food and Drug Administration from May 19, 2025 to May 22, 2025. The inspection covered six major systems including quality management system, materials, production, packaging and labeling, equipment facilities, and laboratory controls. Recently, Ruibo's Suzhou facility received an on-site inspection report issued by the US FDA, indicating that it had passed the cGMP on-site inspection. The successful inspection shows that Ruibo Suzhou meets the requirements of the US FDA in terms of drug cGMP quality management system and production environment facilities, providing a solid guarantee for the company's continued expansion into international markets and positively impacting the expansion of global standardized markets.